Get the Stockscreener App
3.00
0.00%
0.00
After Hours:
3.00
Elicio Therapeutics Inc stock is traded at $3.00, with a volume of 254.90K.
It is up +0.00% in the last 24 hours and down -25.00% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
See More
Previous Close:
$3.00
Open:
$3.08
24h Volume:
254.90K
Relative Volume:
0.16
Market Cap:
$78.79M
Revenue:
-
Net Income/Loss:
$-40.19M
P/E Ratio:
-1.2796
EPS:
-2.3444
Net Cash Flow:
$-38.49M
1W Performance:
-1.32%
1M Performance:
-25.00%
6M Performance:
-64.50%
1Y Performance:
-69.67%
1-Day Range:
$2.97
$3.20
1-Week Range:
$2.96
$3.2199
52-Week Range:
$2.66
$16.00
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
3.00 | 78.79M | 0 | -40.19M | -38.49M | -2.3444 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Ladenburg Thalmann | Buy |
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elicio Therapeutics Market Sentiment - Benzinga
ELTX|Elicio Therapeutics Inc|Price:3.000|Chg%:-0.150 - TradingKey
TradingKey - TradingKey
Elicio Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELTX - TradingView
Elicio Therapeutics Inc (ELTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Elicio Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Ladenburg Thalmann initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
Elicio Therapeutics (ELTX) awards 64,643 stock options to R&D and medical chief - Stock Titan
Elicio Therapeutics (ELTX) grants 52,832 stock options to Chief Scientific Officer - Stock Titan
Elicio Therapeutics (ELTX) awards 60,833 stock options to its CFO - Stock Titan
Elicio Therapeutics (ELTX) CEO awarded 186,944 stock options at 3.2000 - Stock Titan
ELTX Stock Price, Quote & Chart - ChartMill
Moti Investments discloses 6.1% stake in Elicio Therapeutics (NASDAQ: ELTX) - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Price-Driven Insight from (ELTX) for Rule-Based Strategy - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Connect - ACCESS Newswire
Enterprise value to revenue forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Reach Out - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc.ELTX - PR Newswire
Why Is ELTX Stock Falling Today? - Stocktwits
[SCHEDULE 13G/A] Elicio Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-07-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:ELTX | Press Release - Stockhouse
Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ELICIO THERAPEUTICS ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING - Moomoo
Elicio Therapeutics closes $15 million stock offering - Investing.com India
Elicio Therapeutics Closes $15 Million Registered Direct Offering - marketscreener.com
Elicio Therapeutics closes $15 million stock offering By Investing.com - Investing.com South Africa
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elicio Therapeutics, Inc. (ELTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Elicio Therapeutics, Inc. (ELTX) Investigation: Bronstein, Gewirt - The National Law Review
Enterprise value to EBIT forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo
Price to sales forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
Enterprise value to EBITDA forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Elicio Therapeutics, Inc. (ELTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Elicio Therapeutics stock tumbles on $15M offering - Investing.com
Elicio Therapeutics stock tumbles on $15M offering By Investing.com - Investing.com India
Form 424B5 Elicio Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Form 424B5 Elicio Therapeutics, - StreetInsider
Elicio Therapeutics (ELTX) raises ~$15.0M via 4.38M-share placement - Stock Titan
Another Blow For ELTX? Elicio Raises Fresh Capital Weeks After Trial Disappointment - Yahoo Finance
Elicio Therapeutics raises $15M in registered direct offering By Investing.com - Investing.com Australia
Elicio Therapeutics Prices $15 Million Registered Direct Offering at $3.43; Signs Purchase, Placement Pacts - TradingView
Elicio Therapeutics (ELTX) prices $15M registered direct equity offering - Stock Titan
Elicio Therapeutics Prices $15 Million Direct Offering - marketscreener.com
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):